Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 3.71M | 1.16M | 0.00 | 0.00 | 873.00K |
Gross Profit | -1.66M | -1.31M | -555.00K | -588.00K | 873.00K |
EBITDA | -41.89M | -59.03M | -58.20M | -42.70M | -22.02M |
Net Income | -46.63M | -60.24M | -55.82M | -43.18M | -22.88M |
Balance Sheet | |||||
Total Assets | 30.06M | 56.96M | 68.75M | 99.20M | 40.52M |
Cash, Cash Equivalents and Short-Term Investments | 6.92M | 34.47M | 45.88M | 80.24M | 34.63M |
Total Debt | 11.69M | 17.84M | 3.59M | 3.49M | 6.93M |
Total Liabilities | 15.72M | 29.77M | 26.72M | 20.99M | 10.06M |
Stockholders Equity | 13.58M | 25.05M | 37.91M | 72.70M | 30.46M |
Cash Flow | |||||
Free Cash Flow | -44.10M | -61.76M | -36.89M | -24.58M | -20.53M |
Operating Cash Flow | -38.22M | -56.01M | -33.01M | -23.13M | -19.64M |
Investing Cash Flow | 14.90M | -12.23M | -20.59M | -1.45M | -890.00K |
Financing Cash Flow | 16.65M | 43.17M | 2.70M | 79.45M | 30.33M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $98.37M | 12.66 | 5.00% | ― | 0.29% | -22.13% | |
66 Neutral | $75.81M | 41.77 | 3.46% | ― | 24.75% | -61.29% | |
64 Neutral | ¥338.86B | 10.95 | -2.99% | 2.58% | 11.77% | -10.17% | |
55 Neutral | $195.20M | ― | -14.10% | ― | 5.73% | 72.50% | |
46 Neutral | $109.90M | ― | -60.68% | ― | 19.84% | 5.77% | |
45 Neutral | $333.48M | ― | -30.11% | ― | 15.32% | 15.73% | |
43 Neutral | $19.30M | ― | -241.40% | ― | 219.67% | 56.69% |
On June 20, 2025, Beyond Air, Inc. held a special meeting of stockholders where a reverse stock split proposal was approved. The proposal grants the board of directors the authority to implement a reverse stock split at a ratio between 1-for-10 and 1-for-50 within a year, potentially impacting the company’s stock structure and market perception.
The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
On June 16, 2025, Beyond Air appointed Robert Goodman to its Board of Directors, bringing his extensive experience in healthcare leadership to the company. Additionally, Beyond Air announced the submission of a premarket approval supplement to the FDA for its second-generation LungFit PH device, which could significantly enhance its market potential. The company reported a 220% increase in annual revenue for the fiscal year ending March 31, 2025, driven by the demand for LungFit PH and international expansion. Despite a net loss, Beyond Air’s strategic moves, including new distribution partnerships and regulatory approvals, position it for a pivotal year ahead.
The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.